The oncology market is expected to reach $150BN by 20201 driven by a number of new launches and increasing costs for new cancer drugs.
read more...
Pharmaceutical sales are driven by a multiplicity of elements and factors. First, of course, is the drug’s efficacy and safety profile.
read more...
CMS created the Center for Medicare and Medicaid Innovation (Innovation Center) in 2010 as part of the Patient Protection and Affordable Care Act. Their purpose is to test innovative payment and delivery systems with the goal of improving quality of care.
read more...
The sales force is by far one of the most impactful promotional drivers available to biotech / pharma organizations and is often the first choice in allocating brand promotional spend. Therefore, it is critical to appropriately resource sales force teams to maximize share of voice in the market and adequately support customer needs and requests. Traditionally, there has been four approaches to sizing a sales force
read more...
The March 6, 2015 FDA approval of Sandoz’s Zarxio as a biosimilar alternative to Amgen’s Neupogen marked a key milestone in the US healthcare industry as the first product to be passed under the Biologics Price Competition and Innovation Act of 2009
read more...
Since 2014, 159 Solutions has focused on providing thoughtful analytical partnership to our clients in life sciences and healthcare. Thanks to the success of our collaborations, we have reached the point where we have an opportunity to share our unique experiences and perspectives with a wider audience.
read more...